Courtesy: The Saudi Gazette
Rajrishi Singhal, Senior Geo-economics fellow, Gateway House, has been quoted in an article on India-Russia's new diamond trade cooperation. This article has been published by The Saudi Gazette
Courtesy: Vietnam Plus
Rajrishi Singhal, Senior Geo-economics fellow, Gateway House, has been quoted in an article on India-Russia's new diamond trade cooperation. This article has been published by Vietnam Plus
Courtesy: Ino Pressa
Amit Bhandari, Author, Energy and Environment Fellow, has been quoted in an article on Putin's visit to India, which will be the second time the two meet in six months. This article has been published by Ino Pressa
Courtesy: Newsru
Amit Bhandari, Author, Energy and Environment Fellow, has been quoted in an article on Putin's visit to India, which will be the second time the two meet in six months. This article has been published by the Newsru
Courtesy: The Financial Times
Sameer Patil, Associate Fellow, National Security, Ethnic Conflict and Terrorism, Gateway House has been quoted in an article on Russia and India agreeing to establish nuclear reactors in India during Putin's visit to Delhi. This article has been published by The Financial Times
Courtesy: wikimedia
Rajni Bakshi, senior Gandhi peace fellow at Gateway House, comments on the significance of the world climate talks in Lima, Peru, for India
Courtesy: wikimedia
Sameer Patil, associate national security fellow at Gateway House, comments on India-Russia security relations ahead of President Putin’s visit
Courtesy: MEA/Government of India
Amit Bhandari, energy and environment fellow at Gateway House, comments on India and Russia’s energy relationship
Courtesy: Wikimedia
Amit Bhandari, energy and environment fellow at Gateway House, comments on the recent outcomes regarding nuclear energy cooperation from President Putin’s visit to India
Earlier this year, Gilead Sciences, a California-based pharmaceutical company, made the headlines for an unusual, positive move in the fraught property rights space. It entered into a license agreement with seven Indian pharmaceutical companies to manufacture lower cost versions of Sovaldi, its popular Hepatitis C drug
